MA30824B1 - Radiofluration - Google Patents

Radiofluration

Info

Publication number
MA30824B1
MA30824B1 MA31834A MA31834A MA30824B1 MA 30824 B1 MA30824 B1 MA 30824B1 MA 31834 A MA31834 A MA 31834A MA 31834 A MA31834 A MA 31834A MA 30824 B1 MA30824 B1 MA 30824B1
Authority
MA
Morocco
Prior art keywords
compounds
radiofluration
radiactively
groupings
meaning
Prior art date
Application number
MA31834A
Other languages
English (en)
Inventor
Ananth Srinivasan
Lutz Lehmann
Ulrike Roehn
Timo Stellfeld
Ulrich Klar
Simon Ametamey
Aileen Hoehne
Linjing Mu
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06076823A external-priority patent/EP1908472A1/fr
Priority claimed from EP06076869A external-priority patent/EP1911452A1/fr
Priority claimed from EP07090043A external-priority patent/EP1970064A1/fr
Priority claimed from EP07090079A external-priority patent/EP1985624A3/fr
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA30824B1 publication Critical patent/MA30824B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0896—Compounds with a Si-H linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX COMPOSÉS APPROPRIÉS OU DÉJÀ MARQUÉS RADIOACTIVEMENT AU 18F, DES PROCÉDÉS DE FABRICATION DE TELS COMPOSÉS ET L'UTILISATION DE TELS COMPOSÉS À DES FINS D'IMAGERIE DIAGNOSTIQUE. DE TELS COMPOSÉS MARQUÉS SONT CARACTÉRISÉS PAR LA FORMULE II, LES GROUPEMENTS F, R1, R2, B1.2, Y1.2, Z1.2 ET E AYANT UNE SIGNIFICATION TELLE QUE DÉFINIE DANS LA SPÉCIFICATION ET LES REVENDICATIONS.
MA31834A 2006-10-02 2009-04-30 Radiofluration MA30824B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06076823A EP1908472A1 (fr) 2006-10-02 2006-10-02 Dérivés de silicone pour l'imagerie TEP
EP06076869A EP1911452A1 (fr) 2006-10-11 2006-10-11 Dérivés de silicone pour l'imagerie TEP
EP07090043A EP1970064A1 (fr) 2007-03-12 2007-03-12 Dérivés de silicone pour l'imagerie TEP
EP07090079A EP1985624A3 (fr) 2007-04-23 2007-04-23 Procédé simple de radiofluorination de composés actifs biologiquement ou de biomolécules

Publications (1)

Publication Number Publication Date
MA30824B1 true MA30824B1 (fr) 2009-10-01

Family

ID=39030886

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31834A MA30824B1 (fr) 2006-10-02 2009-04-30 Radiofluration

Country Status (21)

Country Link
US (1) US20090035215A1 (fr)
EP (1) EP2074135A2 (fr)
JP (1) JP2010505776A (fr)
KR (1) KR20090085599A (fr)
AR (1) AR062795A1 (fr)
AU (1) AU2007304508A1 (fr)
BR (1) BRPI0719956A2 (fr)
CA (1) CA2664700A1 (fr)
CO (1) CO6180444A2 (fr)
CR (1) CR10703A (fr)
IL (1) IL197817A0 (fr)
MA (1) MA30824B1 (fr)
MX (1) MX2009003617A (fr)
NO (1) NO20091735L (fr)
PA (1) PA8747601A1 (fr)
PE (1) PE20081173A1 (fr)
SV (1) SV2009003205A (fr)
TN (1) TN2009000100A1 (fr)
TW (1) TW200820988A (fr)
UY (1) UY30596A1 (fr)
WO (1) WO2008040441A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627486T3 (es) 2010-01-25 2017-07-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Biomoléculas sililadas
JP5717138B2 (ja) * 2011-05-23 2015-05-13 独立行政法人産業技術総合研究所 タンパク質固定化表面修飾材料
WO2014196540A1 (fr) * 2013-06-06 2014-12-11 日産化学工業株式会社 Composé alcoxysilane, agent d'alignement de cristaux liquides, film d'alignement de cristaux liquides et élément d'affichage à cristaux liquides
JP7266365B2 (ja) * 2015-05-26 2023-04-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 分子および生体分子の１８ｆ標識化に有用な新規な複素芳香環フッ化ケイ素アクセプタおよびその調製方法
GB2581619A (en) 2017-09-15 2020-08-26 Univ California Inhibition of aminoacylase 3 (AA3) in the treatment of cancer
WO2021226076A1 (fr) * 2020-05-04 2021-11-11 The Research Foundation For The State University Of New York Composition d'agent d'imagerie pour tomographie par émission de positrons et procédé de détection d'infection bactérienne
ES3021138T3 (en) * 2020-09-28 2025-05-26 National Institutes For Quantum Science And Tech Method for producing radioactive labeled substance, device for producing radioactive labeled substance, and method for evaporating and concentrating radioactive metal nuclide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
US5732578A (en) * 1995-02-24 1998-03-31 Hyundai Metal Co., Ltd. Device for maintaining the horizontality of a door lock lever
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6855715B1 (en) * 1999-06-14 2005-02-15 Eli Lilly And Company Serine protease inhibitors
WO2002044144A2 (fr) * 2000-11-30 2002-06-06 Advanced Research And Technology Institute, Inc. Utilisation de nucleophiles pour preparer des agents d'imagerie radiomarques, et composes associes
GB0206750D0 (en) * 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
EP1597270A2 (fr) * 2003-02-20 2005-11-23 University of South Florida Inhibiteurs peptidomimetiques de l'activite de stat3 et utilisations medicales de ceux-ci
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
CA2555597C (fr) * 2004-02-13 2016-06-14 The University Of British Columbia Composes et compositions radiomarques, leurs precurseurs et leurs procedes de production
US20080029548A1 (en) * 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package

Also Published As

Publication number Publication date
WO2008040441A2 (fr) 2008-04-10
JP2010505776A (ja) 2010-02-25
MX2009003617A (es) 2009-04-22
PE20081173A1 (es) 2008-11-06
NO20091735L (no) 2009-06-30
SV2009003205A (es) 2009-10-19
TN2009000100A1 (en) 2010-08-19
UY30596A1 (es) 2008-05-02
AU2007304508A1 (en) 2008-04-10
PA8747601A1 (es) 2009-08-26
IL197817A0 (en) 2009-12-24
CO6180444A2 (es) 2010-07-19
AU2007304508A8 (en) 2009-05-14
KR20090085599A (ko) 2009-08-07
EP2074135A2 (fr) 2009-07-01
CA2664700A1 (fr) 2008-04-10
US20090035215A1 (en) 2009-02-05
TW200820988A (en) 2008-05-16
AR062795A1 (es) 2008-12-03
CR10703A (es) 2009-06-25
WO2008040441A3 (fr) 2009-01-08
BRPI0719956A2 (pt) 2014-04-29

Similar Documents

Publication Publication Date Title
MA30780B1 (fr) Composes et procedes associes a des agents etiquetes 18f
MA31884B1 (fr) Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3
MA31605B1 (fr) Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
EP2119443A4 (fr) Composition destinée à la prévention ou au traitement d'une maladie associée à un thrombus ou à un embole
MA32171B1 (fr) Compose heterocyclique
EP2297335A4 (fr) Procédés de diagnostic d'un rejet d'une allogreffe de rein à l'aide d'un profilage d'expression génomique ou protéomique
EP2142628A4 (fr) Composés au magnésium solubles à l'eau convenant comme agents nettoyants, et procédés d'utilisation correspondants
EP2044091A4 (fr) Composés destinés au traitement d'une maladie périodontale
EP1601248A4 (fr) Utilisation de sang de cordon ombilical pour traiter des individus presentant une maladie, un trouble ou une pathologie
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
EP2203402A4 (fr) Procédés de synthèse d'oléfines fluorées
MA27987A1 (fr) Derives nitro-oxy de losartan, valsatan, candesartan, telmisartan, eprosartan et olmesartan comme bloqueurs des recepteurs de l'angiontensine-ii pour le traitement des maladies cardiovasculaires.
MA31000B1 (fr) Derives 2-aza-bicyclo[3.1.0]hexane
MA31759B1 (fr) Compose amide
BRPI0813341A2 (pt) " uso de compostos, composições curáveis, e, uso de composições curáveis ".
EP1960016A4 (fr) Méthode pour élimination extracorporelle d'un microbe pathogène, d une cellule inflammatoire ou d une protéine inflammatoire du sang
MA31596B1 (fr) Nouveaux herbicides
MA31623B1 (fr) Nouveaux herbicides
EP1835013A4 (fr) Formule d'huile lubrifiante
MA28269A1 (fr) Arylpyrazoles substitués servant d'agents parasiticides
EP2385114A4 (fr) Diagnostic de traitement d'un cancer à l'aide d'un anticorps anti-tm4sf20
MA30331B1 (fr) ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION
WO2008043101A3 (fr) Imagerie préopératoire de structures hépatobiliaires
MA31526B1 (fr) Nouveaux herbicides
MA29485B1 (fr) Motilides